Gossamer Bio, Inc. (GOSS) — 8-K Filings

8-K Filings (13)

• Gossamer Bio Faces Delisting Concerns — Apr 9, 2026 Risk: high
  Gossamer Bio, Inc. filed an 8-K on April 9, 2026, to report a notice of delisting or failure to satisfy a continued listing rule or standard, as of April 8, 202
• Gossamer Bio Reports Unregistered Equity Sales — Sep 25, 2025 Risk: medium
  Gossamer Bio, Inc. filed an 8-K on September 25, 2025, reporting unregistered sales of equity securities on September 24, 2025. The filing does not provide spec
• Gossamer Bio Files 8-K: Board Changes & Shareholder Votes — Jun 25, 2025 Risk: medium
  Gossamer Bio, Inc. announced on June 25, 2025, changes in its board of directors and executive compensation arrangements. The filing also covers the submission
• Gossamer Bio Files 8-K Report — Jun 16, 2025 Risk: low
  On June 16, 2025, Gossamer Bio, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Other Events, with no specific financial fi
• Gossamer Bio Files 8-K on Financials — May 15, 2025 Risk: low
  Gossamer Bio, Inc. filed an 8-K on May 15, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and ex
• Gossamer Bio Files 8-K for Other Events — Feb 19, 2025 Risk: low
  Gossamer Bio, Inc. filed an 8-K on February 19, 2025, to report other events. The filing does not contain specific details about the nature of these events, but
• Gossamer Bio Faces Nasdaq Delisting Notice — Sep 13, 2024 Risk: high
  Gossamer Bio, Inc. announced on September 11, 2024, that it received a notice from the Nasdaq Stock Market indicating non-compliance with listing rules. The com
• Gossamer Bio to be Acquired by Cerberus for $1.2B — Jul 18, 2024 Risk: medium
  Gossamer Bio, Inc. announced on July 18, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of Cerberus Capital Management, L.
• Gossamer Bio Reports on Shareholder Vote Matters — Jun 10, 2024 Risk: low
  Gossamer Bio, Inc. filed an 8-K on June 10, 2024, reporting on matters submitted to a vote of security holders on June 6, 2024. The filing details the company's
• Gossamer Bio Faces Delisting Concerns — May 24, 2024 Risk: high
  Gossamer Bio, Inc. filed an 8-K on May 24, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The company is base
• Gossamer Bio Terminates J&J Agreement, Reports Equity Sales — May 6, 2024 Risk: medium
  Gossamer Bio, Inc. announced on May 3, 2024, the termination of its material definitive agreement with Johnson & Johnson Innovation LLC. The company also report
• Gossamer Bio Appoints New CEO, Dr. Gujrathi Takes Helm — Mar 12, 2024 Risk: medium
  Gossamer Bio, Inc. announced on March 11, 2024, the appointment of Dr. Sheila Gujrathi as Chief Executive Officer and a member of the Board of Directors, effect
• Roivant to Acquire Gossamer Bio for $1.7B — Mar 4, 2024 Risk: medium
  Gossamer Bio, Inc. announced on March 4, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of The Roivant Sciences Ltd. for $

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX